Your browser is no longer supported. Please, upgrade your browser.
NVO Novo Nordisk A/S daily Stock Chart
Novo Nordisk A/S
Index- P/E19.99 EPS (ttm)2.08 Insider Own26.40% Shs Outstand1.99B Perf Week4.85%
Market Cap82.58B Forward P/E17.53 EPS next Y2.37 Insider Trans0.00% Shs Float1.36B Perf Month-8.93%
Income5.30B PEG1.87 EPS next Q0.56 Inst Own10.00% Short Float0.20% Perf Quarter-24.24%
Sales16.21B P/S5.09 EPS this Y34.30% Inst Trans0.43% Short Ratio0.83 Perf Half Y-25.47%
Book/sh2.47 P/B16.80 EPS next Y6.81% ROA41.50% Target Price57.00 Perf Year-20.53%
Cash/sh1.12 P/C36.93 EPS next 5Y10.70% ROE84.90% 52W Range39.03 - 57.43 Perf YTD-26.59%
Dividend1.41 P/FCF27.30 EPS past 5Y22.40% ROI85.00% 52W High-27.73% Beta0.76
Dividend %3.40% Quick Ratio0.90 Sales past 5Y12.20% Gross Margin84.80% 52W Low6.33% ATR0.73
Employees42265 Current Ratio1.30 Sales Q/Q1.50% Oper. Margin43.40% RSI (14)44.44 Volatility1.23% 1.42%
OptionableYes Debt/Eq0.01 EPS Q/Q21.50% Profit Margin32.70% Rel Volume1.16 Prev Close41.04
ShortableYes LT Debt/Eq0.00 EarningsOct 28 BMO Payout45.20% Avg Volume3.25M Price41.50
Recom3.00 SMA200.39% SMA50-6.47% SMA200-18.81% Volume3,762,844 Change1.12%
Sep-23-16Initiated Piper Jaffray Neutral
Sep-13-16Upgrade Exane BNP Paribas Neutral → Outperform
Sep-09-16Downgrade JP Morgan Overweight → Neutral
Sep-01-16Downgrade Morgan Stanley Overweight → Equal-Weight
Aug-31-16Upgrade HSBC Securities Reduce → Hold
Aug-08-16Downgrade BofA/Merrill Buy → Neutral
Aug-28-15Initiated Leerink Partners Mkt Perform $56
Jun-09-15Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-15-15Initiated Societe Generale Sell
May-28-13Upgrade Deutsche Bank Sell → Hold
Mar-31-10Initiated Deutsche Bank Hold
Mar-30-10Downgrade Mehta Partners Outperform → Market Perform
Feb-24-10Upgrade Jefferies & Co Hold → Buy
Jan-15-10Downgrade Jefferies & Co Buy → Hold
Sep-11-09Initiated Jefferies & Co Buy
Aug-07-09Downgrade UBS Buy → Neutral
Aug-07-09Downgrade JP Morgan Overweight → Neutral
May-12-09Initiated Piper Jaffray Buy
Apr-24-09Upgrade Citigroup Hold → Buy
Mar-26-09Upgrade UBS Neutral → Buy
Oct-22-16 08:00AM  5 Most Successful Quant Hedge Funds And Their Top Picks at Insider Monkey
Oct-20-16 11:06AM  Novo Nordisk A/S : NVO-US: Dividend Analysis : August 15th, 2016 (record date) : By the numbers : October 20, 2016
Oct-19-16 10:06AM  Eli Lilly and Co.s 3Q16 Estimates: Endocrine Franchise
Oct-17-16 07:49AM  Get Paid While You Wait: 3 Top Dividend Stocks in Big Pharma at Motley Fool
Oct-13-16 08:07AM  3 Attractive Income Stocks Whose Dividends Could Double at Motley Fool
08:06AM  Which Healthcare Company Is the Best Dividend Stock? at Motley Fool
Oct-12-16 10:58AM  Two Dividend Growth Stocks on My Radar at Insider Monkey
Oct-11-16 09:30AM  The Zacks Analyst Blog Highlights: Alphabet, Novo Nordisk, Enterprise Products Partners, Textron and Xerox
Oct-10-16 04:04PM  Bristol-Myers, Staples Fall Into Mondays 52-Week Low Club at 24/7 Wall St.
01:57PM  Top Research Reports for Alphabet, Novo Nordisk & Enterprise Products
01:00PM  4 Blue Chip Stocks For Global Investors at Forbes
Oct-09-16 06:58AM  Why Novo Nordisk Stock Fell 10.2% in September at Motley Fool
Oct-07-16 07:26PM  3 Beaten-Up Big Pharma Stocks: Are They Bargains Now? at Motley Fool
Oct-06-16 11:34AM  Novo Nordisk Is Being Ignored
Oct-05-16 10:32AM  ETFs with exposure to Novo Nordisk A/S : October 5, 2016
Oct-04-16 08:04AM  Will Novo Nordisks Core Capabilities Be Enough to Differentiate Its Research Pipeline?
Oct-03-16 12:09PM  Novo Nordisk (NVO) Stock Drops, Explores Inventing New Forms of Insulin
11:05AM  What Will Drive Novo Nordisks Growth in Diabetes and Hemophilia?
10:06AM  Diabetes Care Market Is Expected to See Fast Growth
10:04AM  Novo Nordisk Expects to Witness Strong Growth from New Product Launches
08:06AM  Volume Growth and Product Mix to Drive NVOs Insulin Sales
08:04AM  Can Novo Nordisk Continue to Maintain Market Share in Modern Insulin?
12:25AM  [$$] Novo Nordisk Bets on Riskier Insulin Research at The Wall Street Journal
Oct-02-16 07:28PM  [$$] Novo Nordisk Bets on Riskier Insulin Research at The Wall Street Journal
Sep-30-16 06:04PM  Novo Nordisk Is Expected to See Strong Growth in Insulin Segment
03:56PM  Novo Nordisk Is Number One Player in Diabetes Care Market in 2016
11:05AM  Understanding Strong Growth Trends in Insulin and Novo Nordisks Profitability
10:05AM  Novo Nordisk Continues to Be a Leader in the Global Insulin Market
08:05AM  Why Novo Nordisk Expects Double-Digit Growth in Diabetes Care in 2016
Sep-29-16 08:58PM  [$$] Business Watch at The Wall Street Journal
05:04PM  Novo Nordisk Is Focusing on These Strategic Areas in 2016
03:04PM  Diabetes Care Market Expected to Offer Strong Growth for Novo Nordisk
02:03PM  [$$] Novo Nordisk Announces Job Cuts at The Wall Street Journal
01:34PM  The Diabetes Price War Claims Casualties at Bloomberg
01:16PM  Geographic Diversification Has Helped Novo Nordisk Offset Modest US Sales
11:55AM  Here's Why Shares of Novo Nordisk are Lower Thursday at TheStreet
06:53AM  Novo Nordisk Takes Axe to Workforce as Growth Falters
05:06AM  Job Cuts Are About Finding Right Balance, Says Soerensen
05:04AM  Job Cuts Are About Finding Right Balance, Says Soerensen at Bloomberg
04:16AM  Danish drug maker Novo Nordisk to lay off 1,000 employees
03:43AM  Novo Nordisk to ax 1,000 jobs in cost-cutting drive
02:28AM  Novo Nordisk Plans to Cut 1,000 Jobs Amid Diabetes Price War at Bloomberg
Sep-28-16 05:11PM  Novo Nordisk says to cut 1,000 jobs AFP
05:57AM  Kroger, Oil Tanker Firm Sail into Tuesdays 52-Week Low Club
Sep-27-16 01:37PM  American Express Company (AXP), Rockwell Collins Inc. (COL) & More: Heres Why These Stocks Are Trending Today at Insider Monkey
11:38AM  Stocks Up After 1st Presidential Debate; Why Tesla Looks Healthiest In Weeks
Sep-23-16 07:15AM  Coverage initiated on Novo Nordisk A/S by Piper Jaffray
Sep-21-16 11:30AM  Novo Nordisk to supply insulin at discount to poorest nations Reuters
Sep-19-16 04:25AM  Holy Grail of Oral Insulin Gives Way to Other Tablets at Novo at Bloomberg
Sep-17-16 03:00PM  There's something odd about the way insulin prices change
Sep-16-16 03:48AM  Novo Nordisk's diabetes drug semaglutide cuts heart risk by 26 percent
12:02AM  A 93-year-old drug that can cost more than a mortgage payment tells us everything that's wrong with American healthcare
Sep-15-16 12:36PM  Great Place to Work® and Fortune name Novo Nordisk as one of the country's best workplaces for women PR Newswire
11:11AM  A 93-year-old drug that some children can't live without tells us everything that's wrong with American healthcare
09:54AM  Novo Nordisk (NVO) Presents Data on Obesity Drug Saxenda
Sep-14-16 06:04PM  How Sanofis Various Franchises Performed in 2Q16
04:04PM  How Sanofis Franchises Could Perform into 2017
Sep-12-16 03:59PM  Novo Nordisk (NVO) Stock Advances, Deutsche Bank Upgrades
11:28AM  ETFs with exposure to Novo Nordisk A/S : September 12, 2016
11:04AM  After Spinning Off Hemophilia Business, Whats Next for Biogen?
09:24AM  Why Novo Nordisk Stock Dropped 18.9% in August at Motley Fool
01:01AM  Pills and Pens Bring Hope for Drug Companies in Diabetes Crunch
Sep-10-16 01:10PM  Barron's Picks And Pans: Vodafone, BorgWarner, Novo Nordisk And More
01:04PM  NOVO NORDISK A S Financials
12:01AM  A Preview of This Weekend's Barron's at
12:01AM  [$$] Denmark's Novo Nordisk Plots a Recovery at
Sep-09-16 04:04PM  GlaxoSmithKlines Fundamentals Show It Has Lots of Room to Run
01:50PM  Inside The FDA: Eli Lilly and Co (LLY) Jardiance Aims at Proving Cardiovascular Benefit in Diabetes, Will FDA Agree? at Insider Monkey
08:14AM  Pharma Stock Roundup: Drug Pricing Remains in Focus, Merck Drops Odanacatib
Sep-07-16 07:04PM  Want to Know Why DISAX Has Done Well Year-to-Date?
Sep-06-16 01:38PM  Inside the FDA: Why Sanofi SA (ADR) (SNY) IGlarLixi Was Delayed But Novo Nordisk A/S (ADR) (NVO) IDegLira Wasnt at Insider Monkey
Sep-05-16 08:31AM  Novo Nordisk's IDegLira Review Period Extended in the U.S.
08:00AM  VeriFone (PAY), Gilead (GILD) Among 5 Stocks That Hit 52-Week Lows Last Week at Insider Monkey
Sep-02-16 12:52PM  [$$] Lars Fruergaard Jorgensen a model for 'Novo Nordisk Way' at Financial Times
08:04AM  Analyzing Eli Lillys Blockbuster Endocrinology Drugs
Sep-01-16 12:49PM  [$$] Novo Nordisk: long Lars-ting at Financial Times
12:40PM  [$$] Novo Nordisk chief executive retires in shake-up at Financial Times
11:32AM  Novo Nordisk (NVO) Stock Falls, CEO Rebien Sorensen Retires
10:11AM  Novo Taps Veteran as CEO to Tackle Unprecedented Competition at Bloomberg
09:42AM  Novo Nordisk's veteran CEO Lars Rebien Sorensen to step down
06:17AM  Novo Nordisk CEO to step down after 16 years
02:11AM  Novos Chief to Retire, Veteran Joergensen to Succeed Him at Bloomberg
Aug-26-16 08:20AM  Sanofi Just Cant Catch a Break, Knocking at Major Support Again at 24/7 Wall St.
Aug-24-16 09:04AM  Why Did Novo Lower 2016 Sales Guidance?
Aug-23-16 07:04PM  Performance of AstraZenecas Growth Platforms in 2Q16
11:04AM  Whats Challenging Novos Leadership in the US Diabetes Space?
09:04AM  What Are the Prospects for Novos Biopharmaceuticals Segment?
Aug-22-16 01:14PM  Why Did Novos Valuation Multiple Fall Recently?
01:14PM  How Did Novos Diabetes and Obesity Care Segment Perform in 1H16?
11:54AM  FDAs Sanofi SA (ADR) (SNY) Delay Highlights Some Red Flags With IGlarLixi at Insider Monkey
11:48AM  ETFs with exposure to Novo Nordisk A/S : August 22, 2016
09:05AM  Can Allergan Generics Boost Teva Pharmaceuticals 2016 Revenues?
Aug-17-16 05:05PM  Inside Sanofis Valuation Changes
Aug-16-16 02:30PM  Novo Nordisk A/S Focuses on New Drugs at Motley Fool
Aug-15-16 07:30AM  Emisphere Reports Second Quarter 2016 Financial Results GlobeNewswire
Aug-14-16 07:18AM  3 Beaten-Up Big Pharma Stocks: Are They Bargains? at Motley Fool
Aug-12-16 01:17PM  Top 3 Research Reports for August 12, 2016
Aug-11-16 01:00PM  ETFs with exposure to Novo Nordisk A/S : August 11, 2016
Aug-10-16 10:18AM  Novo Nordisk A/S :NVO-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016
09:42AM  Post Earnings Coverage as Novo Nordisk Tops Profit Expectations with 23 Percent Growth
Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity Care, and Biopharmaceuticals. The Diabetes and Obesity Care segment provides insulins, GLP-1 analog, obesity, and oral antidiabetic drugs, as well as other protein related products comprising glucagon, protein related delivery systems, and needles. The Biopharmaceuticals segment offers products in the areas of haemophilia care, growth hormone therapy, and hormone replacement therapy. The company markets and distributes its products through distributors and independent agents in North America, Europe, Japan and South Korea, China, Hong Kong, Taiwan, and other countries. Novo Nordisk A/S has a collaboration agreement with the Langer Laboratory. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.